Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
Date:4/29/2009

SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 20, 2009.

        To access the conference call, follow these instructions:

        Dial: (888) 396-2369 (U.S.); (617) 847-8710 (international)
        Passcode: 82263149 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 20, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 19053055.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. More information on Nektar is available at http://www.nektar.com

                Jennifer Ruddock, 650-631-4954, Nektar Therapeutics


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
2. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
3. Nektar Therapeutics Announces Second Quarter 2008 Results
4. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
5. Nektar Therapeutics Announces First Quarter 2008 Results
6. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Malvern, PA (PRWEB) , ... June 20, 2017 , ... ... that specialize in minimally invasive techniques to treat and manage a wide range of ... a strategic rebranding initiative. With more than 65 centers represented by more than 40 ...
(Date:6/20/2017)... ... June 20, 2017 , ... EdChoice and the American ... choice can promote economic development in economically distressed urban areas. The first report ... report, contributed to the economic development of the city of Santa Ana, California. ...
(Date:6/20/2017)... , ... June 20, 2017 , ... AMC Health ... expansion and success in the clinical trials market. Similar to its approach in demonstrating ... in the clinical trials marketplace by proving the value of eVisits to support virtual ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers ... PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, the dentists identify ... precisely and restore oral health for those who are missing teeth in ...
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month by ... gums in Vancouver, BC, may be developing gingivitis, the first stage of gum ... diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy to ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/24/2017)... Va. , May 24, 2017  ivWatch ... Original Equipment Manufacturer (OEM) Board to enable seamless ... with patient monitoring systems, infusion pumps and other ... OEMs will be able to help health care ... and reduced risks related to IV therapy. ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: